Login
$HBIO
$8.91 -$0.48 (5.11%) Live

$HBIO 8-K/A SEC Filings

Filed On Filing
27 Jun 2025 8-K/A: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

03 Jan 2023 8-K/A: Departure/Election of Directors or Officers; Compensation

Harvard Bioscience “HBIO” is pleased to extend to you a full-time offer of employment as Vice President, Finance based on the terms and subject to the conditions described below. I hope that you will find this new position challenging an...

26 Feb 2020 8-K/A: Results of Operations and Financial Condition

HOLLISTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline issued earlier today by Harvard Bioscience, Inc. (Nasdaq: HBIO), please note that the table titled "Consolidated Statements of Operations" ha...

18 Mar 2019 8-K/A: Results of Operations and Financial Condition

-Reports record Fourth Quarter GAAP and adjusted non-GAAP revenue of $33.9 million, a year-over-year increase of 56% and 24%, respectively-

17 Apr 2018 8-K/A: Financial Statements and Exhibits

We have audited the accompanying consolidated financial statements of Data Sciences International, Inc. and Subsidiaries (the Company), which comprise the consolidated balance sheets as of June 30, 2017 and 2016, the related consolidated...

30 Oct 2017 8-K/A: Departure/Election of Directors or Officers; Compensation

HOLLISTON, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, appointed Katherine Eade and...

08 Nov 2013 8-K/A: Completion of Acquisition or Disposition of Assets

On November 1, 2013, the previously announced spin-off of Harvard Apparatus Regenerative Technology, Inc., or HART, from Harvard Bioscience, Inc. (“us”, “we”, or “the Company”) was completed. On that date, HART became an independent comp...

19 Nov 2009 8-K/A: Financial Statements and Exhibits

Balance sheets as of December 31, 2008 (audited) and June 30, 2009 (unaudited)

06 Oct 2008 8-K/A: Costs Associated with Exit or Disposal Activities

On September 30, 2008, the Company entered into an Asset Purchase Agreement to sell, and sold, its Union Biometrica division, which contained the COPAS flow cytometry product line, and its German subsidiary, Union Biometrica GmbH, repres...

06 Dec 2007 8-K/A: Costs Associated with Exit or Disposal Activities

On November 30, 2007, the Company entered into an Asset Purchase Agreement to sell, and sold, its Genomic Solutions Division and its Belgian subsidiary, Maia Scientific, both of which were part of the Company’s Capital Equipment Business...

17 May 2004 8-K/A: Financial Statements and Exhibits

We have audited the accompanying balance sheet of KD Scientific, Inc. (the “Company”) as of December 31, 2003, and the related statements of operations, shareholder’s equity, and cash flows for the year then ended. These financial statem...

27 May 2003 8-K/A: Financial Statements and Exhibits

QuickLinks -- Click here to rapidly navigate through this document

14 Aug 2001 8-K/A: Financial Statements and Exhibits

Consolidated Financial Statements as of December 31, 1999 and 2000 Together with Auditors' Report

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support